MedPath

PANVACâ„¢-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen

Phase 3
Conditions
Pancreatic Cancer
Registration Number
NCT00088660
Lead Sponsor
Therion Biologics Corporation
Brief Summary

The objectives of this multi-center, randomized, controlled trial are to evaluate the safety and efficacy of PANVAC-VF in combination with Granulocyte-macrophage colony-stimulating factor (GM-CSF) versus best supportive care or palliative chemotherapy.

Detailed Description

PANVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the body can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells. These targets are called Tumor Associated Antigens, or TAA's. This trial will help determine if this vaccine can help fight cancer.

All patients will be required to sign an informed consent prior to the performance of any study-related procedures. Patients will be screened for eligibility within 14 days prior to their anticipated treatment start date (Day 0). Patients who meet all inclusion and exclusion criteria will be centrally randomized into the study and will receive a unique patient identification number and a treatment assignment. The ratio of active treatment to control is 1:1 (PANVAC-VF: best supportive care or palliative chemotherapy).

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
250
Inclusion Criteria
  • Patients > 18 years of age who have been vaccinated against smallpox;
  • Histologically confirmed diagnosis of adenocarcinoma of the pancreas;
  • Patient has metastatic (Stage IV) disease;
  • ECOG performance status 0-1;
  • Failed a gemcitabine-containing chemotherapeutic regimen within 3 months of study entry.
Exclusion Criteria
  • Prior or concurrent immunotherapy for cancer;
  • Radiation therapy within 28 days prior to registration;
  • Systemic corticosteroid therapy (except inhaled or topical steroids) within 28 days of registration;
  • Significant cardiovascular abnormalities or diseases;
  • Known positive for HIV, hepatitis B and/or C;
  • Evidence of immunodeficiency or immune suppression.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (61)

Dayton Oncology Hematology

🇺🇸

Kettering, Ohio, United States

Mary Crowley Medical Research Center

🇺🇸

Dallas, Texas, United States

Temple University Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

Tufts-New England Medical Center, The Neeley Center for Clinical Research

🇺🇸

Boston, Massachusetts, United States

Swedish Cancer Institute

🇺🇸

Seattle, Washington, United States

VA San Diego Healthcare System

🇺🇸

San Diego, California, United States

Jackson Memorial Hospital

🇺🇸

Miami, Florida, United States

Sylvester Cancer Center

🇺🇸

Miami, Florida, United States

VA Medical Center

🇺🇸

Miami, Florida, United States

Greeley Medical Clinic

🇺🇸

Greeley, Colorado, United States

Columbia Presbyterian Medical Center

🇺🇸

New York City, New York, United States

University of South Alabama/ Cancer Research Institute

🇺🇸

Mobile, Alabama, United States

Norwalk Hospital/ Whittingham Cancer Center

🇺🇸

Norwalk, Connecticut, United States

Great Falls Clinic, LLP

🇺🇸

Great Falls, Montana, United States

Jupiter Medical Center

🇺🇸

Jupiter, Florida, United States

Winthrop Oncology/Hematology Division

🇺🇸

Mineola, New York, United States

Moores UCSD Cancer Center

🇺🇸

LaJolla, California, United States

Washington Hospital Cancer Center

🇺🇸

Washington, District of Columbia, United States

Pacific Shores Medical Group

🇺🇸

Long Beach, California, United States

Loveland Hematology Oncology

🇺🇸

Loveland, Colorado, United States

Desert Hematology Oncology Medical Group, Inc

🇺🇸

Rancho Mirage, California, United States

University of Colorado Health Science Center

🇺🇸

Aurora, Colorado, United States

St. Luke's Mountain States Tumor Institute

🇺🇸

Boise, Idaho, United States

Carle Cancer Center

🇺🇸

Urbana, Illinois, United States

Oncology Associates

🇺🇸

Cedar Rapids, Iowa, United States

Gabrail Cancer Center

🇺🇸

Canton, Ohio, United States

Hematology Oncology Consultants, Inc.

🇺🇸

Columbus, Ohio, United States

Nebraska Methodist Hospital

🇺🇸

Omaha, Nebraska, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

Dartmouth Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

Washington University School of Medicine

🇺🇸

St. Louis, Missouri, United States

The Cancer Institute of New Jersey

🇺🇸

New Brunswick, New Jersey, United States

Arlington Cancer Center

🇺🇸

Arlington, Texas, United States

University of Oklahoma Health Science Center

🇺🇸

Oklahoma City, Oklahoma, United States

Virginia Cancer Institute

🇺🇸

Richmond, Virginia, United States

Cancer Care Northwest

🇺🇸

Spokane, Washington, United States

Dr. H. Alejandro Preti, F.A.C.P.

🇺🇸

Houston, Texas, United States

Elkins Pancreas Center

🇺🇸

Houston, Texas, United States

Charleston Cancer Center

🇺🇸

Charleston, South Carolina, United States

Cancer Centers of the Carolinas

🇺🇸

Greenville, South Carolina, United States

Tyler Cancer Center

🇺🇸

Tyler, Texas, United States

Medical Consultants Ltd.

🇺🇸

Milwaukee, Wisconsin, United States

The Sarah Cannon Cancer Center

🇺🇸

Nashville, Tennessee, United States

Texas Cancer Care

🇺🇸

Weatherford, Texas, United States

New York Oncology Hematology

🇺🇸

Albany, New York, United States

USC/Norris Comprehensive Cancer Center

🇺🇸

Los Angeles, California, United States

Scripps Cancer Center

🇺🇸

San Diego, California, United States

Chao Family Comprehensice Cancer Center

🇺🇸

Orange, California, United States

Lombardi Comprehensive Cancer Center

🇺🇸

Washington, District of Columbia, United States

North Idaho Cancer Center

🇺🇸

Coeur D Alene, Idaho, United States

Jayne Gurtler, MD and Laura Brinz, MD APMC

🇺🇸

Metairie, Louisiana, United States

Hematology Oncology Life Center

🇺🇸

Alexandria, Louisiana, United States

Medical Oncology, LLC

🇺🇸

Baton Rouge, Louisiana, United States

Tulane Cancer Center

🇺🇸

New Orleans, Louisiana, United States

Franklin Square Hospital

🇺🇸

Baltimore, Maryland, United States

Maine Center for Cancer Medicine and Blood Disorders

🇺🇸

Scarborough, Maine, United States

Josephine Ford Cancer Center

🇺🇸

Detroit, Michigan, United States

Kansas City Cancer Center

🇺🇸

Kansas City, Missouri, United States

Saint Louis University Cancer Center

🇺🇸

St. Louis, Missouri, United States

Charleston Hematology Oncology

🇺🇸

Charleston, South Carolina, United States

University of Kentucky

🇺🇸

Lexington, Kentucky, United States

© Copyright 2025. All Rights Reserved by MedPath